{"entity":{"id":"pathfinder","kind":"trial","name":"PATHFINDER (first prospective study of the Galleri test)","aka":["PATHFINDER","GRAIL-007","PATHFINDER 1"],"tldr":"The first study to return Galleri results to people without symptoms and follow what happened next; its results appeared in The Lancet in 2023.","summary":"PATHFINDER (NCT04241796) is a single-arm interventional study sponsored by GRAIL, Inc. Its primary outcomes were the number and types of diagnostic tests, and the time needed, to reach a diagnosis after a cancer-signal-detected result. The results paper (Schrag 2023) reports a signal in 92 of 6,621 analysed participants, of whom 35 had cancer.\n\nThe registry record, read on 29 October 2026, gives its status as completed, with 6,662 participants enrolled, a start on 12 December 2019 and primary completion on 1 December 2021.","status":"completed","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT04241796","url":"https://clinicaltrials.gov/study/NCT04241796"}],"tags":[],"related":["pathfinder-2"],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":["galleri"],"companies":["grail"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pathfinder-lancet-2023","paper-pathfinder-design-cancers-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04241796","phase":"not-applicable","setting":"Adults aged 50 and over without symptoms of cancer at US health systems, given the Galleri test alongside usual screening with results returned to their doctors","sponsor":"GRAIL, Inc.","started":"2019-12-12","startedType":"actual","yearReported":2023,"enrolled":6662,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/pathfinder/","neighbours":{"trial":[{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"company":[{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/"}],"paper":[{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/"},{"id":"paper-pathfinder-design-cancers-2021","kind":"paper","name":"The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice","route":"/key-papers/paper-pathfinder-design-cancers-2021/"}]}}